Phytera and Lilly to partner on infectious diseases:
This article was originally published in Clinica
Executive Summary
Phytera and Eli Lilly are to collaborate in research to discover novel agents for the diagnosis and prevention of infectious fungal diseases. Phytera will receive an up-front equity investment, milestone payments and royalties. Lilly, based in Indianapolis, Indiana, will fund the project and have worldwide rights to commercialise any products. As part of the agreement, the Worcester, Massachusetts-based Phytera will provide its natural product chemistry for the bioassay-guided fractionation and Lilly will supply compounds for screening.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.